Table 3.
Multivariate Analysis for Cycle 1 Severe or Febrile Neutropenia (N=2425)
| Variables | Odds Ratio | 95% CI | P |
|---|---|---|---|
| Age, y, ≥65 | 1.297 | .961–1.750 | .089 |
| Prior chemotherapy | 1.925 | 1.345–2.755 | <.001 |
| Baseline labs | |||
| AST>35 u/L | 1.422 | .991–2.041 | .056 |
| Alkaline phosphatase>120 u/L | 1.469 | 1.058–2.040 | .022 |
| Bilirubin>1 mg/dL | 2.152 | 1.235–3.747 | .007 |
| GFR mL/min | .993 | .989–.997 | <.001 |
| WBC×103/mm3 | .930 | .892–.969 | .001 |
| Cancer typea | .004 | ||
| Small cell lung | 1.556 | .641–3.781 | .329 |
| Nonsmall cell lung | .594 | .270–1.309 | .196 |
| Ovary | .515 | .214–1.242 | .140 |
| Breast | .842 | .377–1.880 | .675 |
| Lymphoma | .510 | .219–1.188 | .118 |
| Medications | |||
| Immunosuppressives | 1.554 | 1.105–2.187 | .011 |
| Planned RDI≥85% | 2.018 | 1.449–2.819 | <.001 |
| Chemotherapy | |||
| Anthracyclines | 7.353 | 4.577–11.811 | <.001 |
| Platinum(s) | 1.830 | 1.075–3.117 | .026 |
| Taxanes | 2.850 | 1.860–4.368 | <.001 |
| Alkylating agents | 5.853 | 3.215–10.658 | <.001 |
| Topoisomerase II inhibitors | 8.815 | 4.411–17.619 | <.001 |
| Gemcitabine | 3.092 | 1.696–5.638 | <.001 |
| Topoisomerase I inhibitors | 18.579 | 5.366–64.335 | <.001 |
| Vinorelbine | 4.218 | 1.896–9.385 | <.001 |
| Primary CSF prophylaxis | .120 | .079–.180 | <.001 |
Constant Term = −3.423
RDI indicates relative dose intensity; GFR, glomerular filtration rate; AST, aspartate aminotransferase; WBC, white blood count; CSF, colony-stimulating factors.
a
Reference category: colorectum: OR, 1.00.